SBI Ka Dhamaka! Q3 Results Mein SBI Ne Kiya Kamaal, Tata Steel Ka Global Funda Aur Kahan? 📈

BANKINGFINANCE
Whalesbook Logo
AuthorRiya Kapoor|Published at:
SBI Ka Dhamaka! Q3 Results Mein SBI Ne Kiya Kamaal, Tata Steel Ka Global Funda Aur Kahan? 📈
Overview

Yaar, India mein Q3 FY26 results ka season chal raha hai aur picture bilkul mix hai! Ek taraf State Bank of India (SBI) ne dhamakedaar performance dikhaya hai, toh wahi Tata Steel ne bhi profit mein zabardast jump report kiya hai, lekin reasons thode alag hain. Ab sabki nazar Aurobindo Pharma par hai, jiske results aane wale hain.

Sector Performance Mein Dichotomy: Bank vs Steel!

Q3 FY26 ka ye earnings season dikha raha hai ki saare companies ek jaisa perform nahi kar rahe hain. Kuch toh domestic demand par full focus karke mast chal rahe hain, aur kuch global issues se fight kar rahe hain.

State Bank of India (SBI) ne toh kamaal hi kar diya! Public sector bank ki performance ne sabko impress kiya hai. Early February 2026 tak, SBI ki market cap lagbhag ₹9.84 trillion thi. Unhone profit mein 24% ka tagda jump dikhaya hai, jo ₹21,028 crore tak pahunch gaya. Net interest income bhi 9% badha hai. Waise to analysts ne treasury gains thode kam hone ki wajah se estimates miss kiye hain, par operational strength aur provisions ki wajah se bank mast perform kar raha hai. Stock ne haal hi mein ₹1,090 ka all-time high bhi touch kiya tha. P/E ratio bhi around 11-12 hai, jo peers ke comparison mein sahi lagta hai.

Dusri taraf, Tata Steel ka Q3 FY26 profit 825% year-on-year badhkar ₹2,730 crore ho gaya. Haan, ye number pichhle saal ke low base effect ke karan itna bada dikh raha hai, aur sequential profit mein kami aayi hai. Domestic sales volumes record 6 million tonnes rahe, jisse revenue 6% badhkar ₹57,002 crore ho gaya. Lekin asli game changer yahan domestic demand aur government ke import tariffs hain, jo global oversupply aur kam price se bacha rahe hain. UK jaisi international operations mein abhi bhi loss ho raha hai aur EU ka CBAM bhi future mein dikkat de sakta hai. Market cap around ₹2.46 trillion hai aur TTM P/E 33.5 se 37.5 ke beech hai. Steel sector mein SAIL jaise peers ke comparison mein valuation zyada hai, par ROE sirf 3.89% ke aas-paas hai aur pichhle 5 saal mein sales growth bhi slow rahi hai.

Pharma Sector Ka Kya Scene Hai?

Ab pharma sector ki baari hai. Aurobindo Pharma, jiska market cap lagbhag ₹69,173 crore hai, 10th February 2026 ko apne Q3 FY26 results announce karne wala hai. Company ka P/E ratio 20.2 hai, jo Nifty Pharma Index ke average 33.21 se kaafi kam hai. Analysts ka sentiment mixed hai; ek rating agency ne December 2025 mein 'Buy' se rating ko 'Hold' kar diya tha. Phir bhi, average analyst price target lagbhag 12%+ ka upside dikha raha hai. Pichhle 5 saalon mein sales growth sirf 6.55% rahi hai aur 3 saalon ka ROE bhi 10.2% ke aas-paas hai, jo kuch concerns hain. Dividend payout bhi historically low raha hai.

Bear Case Kya Bolta Hai?

SBI strong dikh raha hai, par unke paas ₹27,42,584 crore ki contingent liabilities bhi hain aur interest coverage ratio bhi low hai. Tata Steel ke liye, 5 saal ki slow sales growth aur low ROE 3.89% ek bada sawal hai ki agar domestic demand kam ho gayi toh margins sustain ho payenge ya nahi. European losses bhi ek structural weakness hain. Aurobindo Pharma ke liye bhi sales growth aur ROE ki chinta hai.

Future Outlook

Jaise jaise results aayenge, market companies ki guidance par nazar rakhega. SBI ki performance Indian banking ki strength dikhati hai, jabki Tata Steel ke liye global pressure se deal karne ki strategy important hogi. Aurobindo Pharma ke results uske international market aur regulatory navigation par roshni dalenge. Ab investors un companies par zyada dhyan de rahe hain jo strong domestic demand aur operational efficiency dikha rahi hain jo global uncertainties mein bhi tik sakti hain.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.